JP2016526875A - クローン病に関連するtnfsf15及びdcr3の変異体 - Google Patents
クローン病に関連するtnfsf15及びdcr3の変異体 Download PDFInfo
- Publication number
- JP2016526875A JP2016526875A JP2016514143A JP2016514143A JP2016526875A JP 2016526875 A JP2016526875 A JP 2016526875A JP 2016514143 A JP2016514143 A JP 2016514143A JP 2016514143 A JP2016514143 A JP 2016514143A JP 2016526875 A JP2016526875 A JP 2016526875A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- subject
- variant
- tnfsf15
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000011231 Crohn disease Diseases 0.000 title claims abstract description 50
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 title claims abstract description 36
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 title claims abstract description 35
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 title claims abstract description 32
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 title claims abstract 8
- 238000000034 method Methods 0.000 claims abstract description 64
- 206010016654 Fibrosis Diseases 0.000 claims description 25
- 230000004761 fibrosis Effects 0.000 claims description 25
- 238000003556 assay Methods 0.000 claims description 15
- 238000003205 genotyping method Methods 0.000 claims description 10
- 230000001681 protective effect Effects 0.000 claims description 6
- 238000011477 surgical intervention Methods 0.000 claims description 3
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 abstract description 28
- 239000000203 mixture Substances 0.000 abstract description 4
- 238000013507 mapping Methods 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 201000010927 Mucositis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 230000036262 stenosis Effects 0.000 description 3
- 208000037804 stenosis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010072877 Intestinal fibrosis Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
この出願は、2013年5月17日に出願のU.S.provisional patent applications No.61/824,932に対する優先権の主張を含む。
例示的実施形態を参照図において例証してある。本明細書において開示される実施形態及び図が限定的というよりはむしろ例証であることが考慮されるべきであることが意図される。
本明細書において引用される全ての参照は、完全に説明するかのように、これらの全体が参照により援用される。別途定義されない限り、本明細書において使用される専門的及び科学的用語は、本発明に属する当業者によって一般に理解されるのと同じ意味を有する。Allen et al., Remington: The Science and Practice of Pharmacy 22nd ed., Pharmaceutical Press (September 15, 2012); Hornyak et al., Introduction to Nanoscience and Nanotechnology, CRC Press (2008); Singleton and Sainsbury, Dictionary of Microbiology and Molecular Biology 3rd ed., revised ed., J. Wiley & Sons (New York, NY 2006); Smith, March’s Advanced Organic Chemistry Reactions, Mechanisms and Structure 7th ed., J. Wiley & Sons (New York, NY 2013); Singleton, Dictionary of DNA and Genome Technology 3rd ed., Wiley−Blackwell (November 28, 2012); 及びGreen and Sambrook, Molecular Cloning: A Laboratory Manual 4th ed., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY 2012)は、本出願において使用される用語の多くに対する一般的手引きを当業者に提供する。抗体を作成する方法の参照については、Greenfield, Antibodies A Laboratory Manual 2nd ed., Cold Spring Harbor Press (Cold Spring Harbor NY, 2013); Kohler and Milstein, Derivation of specific antibody−producing tissue culture and tumor lines by cell fusion, Eur. J. Immunol. 1976 Jul, 6(7):511−9; Queen and Selick, Humanized immunoglobulins, U. S. Patent No. 5,585,089 (1996 Dec);及びRiechmann et al., Reshaping human antibodies for therapy, Nature 1988 Mar 24, 332(6162):323−7を参照されたい。
方法
本発明者は、白色人種、プエルトリコ人(PR)及び韓国人(SK)CDにおけるTNFSF15及びDcR3にわたる民族を越えた細密なマッピングを行った。表1に示した以下の集団に対して行われたイムノチップ遺伝子型決定。
TNFSF15解析
上の結果で示すように、4つのまれな変異体及び9つの共通の変異体は、NJ CDと有意に関連した(表2)。全ての13の関連は、SK CDにおいて繰り返されたが(表4)、まれな変異体は、SK集団においてさらにいっそう一般的であった。
DcR3解析
上の結果は、イントロン6におけるrs6062496がNJ CDと有意に関連することをさらに示した。(図3、表3)。関連をSK CDにおいて確認したが、PR及びAJ CDにおいてはなかった。(表4)。また、rs6062496を狭窄CD、小腸合併症及び外科手術の必要性に対する保護と関連することをさらに同定した(表6)。
TNFSF15−DcR3解析
上の結果は、NJ及びSKにおける有意なDcR3及びTNFSF15遺伝子−遺伝子相互作用がないことをさらに示唆する。(表7)。TNFSF15−DcR3経路によるPARは、NJ CDにおいて32.3%であった。(表8)。SKにおけるTNFSF15変異体によるPARは、アジアのCDにおけるこの座位の優性効果を説明するいずれの集団においても見られる最高のものであった(表8)。
結論
記述した結果に基づいて、本発明者は、NJ CD及びまれなTNFSF15変異体との関連を同定した。この関連は、以前に報告された共通の変異体とは無関係である。これらの変異体は、SK集団においてさらにいっそう一般的であり、及びまた、SK CDと関連する。DcR3は、NJ CDと有意に関連し、SKにおいて繰り返された発見及びこの座位における変異は、狭窄表現型を修飾する。
Claims (17)
- クローン病及び/または線維症に対する被験体におけるリスクを定量化するためのアッセイであって:
被験体から試料を得ること;
TNFSF15及び/またはDcR3遺伝子座位における1つまたは複数の変異体の有無を決定するように適応した遺伝子型決定アッセイに前記試料を供すること;及び
前記TNFSF15及び/またはDcR3遺伝子座位における1つまたは複数の変異体の存在に基いてクローン病及び/または線維症に対する被験体におけるリスクを定量化すること、
を含む、前記アッセイ。 - 請求項1の方法であって、前記変異体は:配列番号.1、配列番号.2、配列番号.3、配列番号.4、配列番号.5、配列番号.6、配列番号.7、配列番号.8、配列番号.9、配列番号.10、配列番号.11、配列番号.12、配列番号.13、配列番号.14、配列番号.15、配列番号.16、配列番号.17、配列番号.18、配列番号.19、配列番号.20、配列番号.21、配列番号.22、配列番号.23、配列番号.24、配列番号.25及び配列番号.26からなる群より選択される1つまたは複数の変異体からなる、前記方法。
- 請求項1の方法であって、前記変異体は、配列番号.3及び/または配列番号.13である、前記方法。
- 請求項1の方法であって、前記変異体は、配列番号.22である、前記方法。
- 請求項1の方法であって、前記被験体は、非ユダヤ人の白色人種、アシュケナジ、韓国人及び/またはプエルトリコ人である、前記方法。
- 請求項1の方法であって、前記被験体は、韓国人であり、及び前記変異体は、配列番号.3、配列番号.13及び/または配列番号.22である、前記方法。
- 請求項1の方法であって、前記変異体は、リスク変異体である、前記方法。
- 請求項1の方法であって、前記変異体は、保護変異体である、前記方法。
- 請求項1の方法であって、前記保護変異体は、構造化、CD、小腸合併症及び/または外科的介入の必要性についての被験体における減少したリスクを定量化する、前記方法。
- 被験体におけるクローン病及び/または線維症に対する感受性を診断する方法であって:
被験体から試料を得ること;
TNFSF15及び/またはDcR3遺伝子座位における1つまたは複数の変異体の有無を決定するように適応した遺伝子型決定アッセイに前記試料を供すること;及び
前記TNFSF15及び/またはDcR3遺伝子座位における1つまたは複数の変異体の存在に基いて被験体におけるクローン病及び/または線維症に対する感受性を診断すること、
を含む、前記方法。 - 請求項10の方法であって、前記変異体は:配列番号.1、配列番号.2、配列番号.3、配列番号.4、配列番号.5、配列番号.6、配列番号.7、配列番号.8、配列番号.9、配列番号.10、配列番号.11、配列番号.12、配列番号.13、配列番号.14、配列番号.15、配列番号.16、配列番号.17、配列番号.18、配列番号.19、配列番号.20、配列番号.21、配列番号.22、配列番号.23、配列番号.24、配列番号.25及び配列番号.26からなる群より選択される1つまたは複数の変異体からなる、前記方法。
- 請求項10の方法であって、前記変異体は、配列番号.3及び/または配列番号.13である、前記方法。
- 請求項10の方法であって、前記変異体は、配列番号.22である、前記方法。
- 請求項10の方法であって、前記被験体は、非ユダヤ人の白色人種、アシュケナジ、韓国人またはプエルトリコ人である、前記方法。
- 請求項10の方法であって、前記被験体は、韓国人であり、及び前記変異体は、配列番号.3、配列番号.13及び/または配列番号.22である、前記方法。
- 被験体におけるクローン病及び/または線維症を治療する方法であって:
被験体から試料を得ること;
TNFSF15及び/またはDcR3遺伝子座位における1つまたは複数の変異体の存在を決定するように適応した遺伝子型決定アッセイに前記試料を供すること;及び
前記クローン病及び/または線維症を治療すること、
を含む、前記方法。 - 請求項16の方法であって、前記変異体は:配列番号.1、配列番号.2、配列番号.3、配列番号.4、配列番号.5、配列番号.6、配列番号.7、配列番号.8、配列番号.9、配列番号.10、配列番号.11、配列番号.12、配列番号.13、配列番号.14、配列番号.15、配列番号.16、配列番号.17、配列番号.18、配列番号.19、配列番号.20、配列番号.21、配列番号.22、配列番号.23、配列番号.24、配列番号.25及び配列番号.26からなる群より選択される1つまたは複数の変異体からなる、前記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361824932P | 2013-05-17 | 2013-05-17 | |
US61/824,932 | 2013-05-17 | ||
PCT/US2014/038468 WO2014186750A2 (en) | 2013-05-17 | 2014-05-16 | Variants of tnfsf15 and dcr3 associated with crohn's disease |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018124311A Division JP2018148931A (ja) | 2013-05-17 | 2018-06-29 | クローン病に関連するtnfsf15及びdcr3の変異体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016526875A true JP2016526875A (ja) | 2016-09-08 |
JP2016526875A5 JP2016526875A5 (ja) | 2017-06-15 |
JP6482533B2 JP6482533B2 (ja) | 2019-03-13 |
Family
ID=51899024
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016514143A Active JP6482533B2 (ja) | 2013-05-17 | 2014-05-16 | クローン病に関連するtnfsf15及びdcr3の変異体 |
JP2018124311A Withdrawn JP2018148931A (ja) | 2013-05-17 | 2018-06-29 | クローン病に関連するtnfsf15及びdcr3の変異体 |
JP2020096798A Withdrawn JP2020127437A (ja) | 2013-05-17 | 2020-06-03 | クローン病に関連するtnfsf15及びdcr3の変異体 |
JP2022093628A Pending JP2022111329A (ja) | 2013-05-17 | 2022-06-09 | クローン病に関連するtnfsf15及びdcr3の変異体 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018124311A Withdrawn JP2018148931A (ja) | 2013-05-17 | 2018-06-29 | クローン病に関連するtnfsf15及びdcr3の変異体 |
JP2020096798A Withdrawn JP2020127437A (ja) | 2013-05-17 | 2020-06-03 | クローン病に関連するtnfsf15及びdcr3の変異体 |
JP2022093628A Pending JP2022111329A (ja) | 2013-05-17 | 2022-06-09 | クローン病に関連するtnfsf15及びdcr3の変異体 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20160090629A1 (ja) |
EP (3) | EP3498867B1 (ja) |
JP (4) | JP6482533B2 (ja) |
KR (3) | KR102295125B1 (ja) |
CN (1) | CN105358713B (ja) |
ES (1) | ES2894963T3 (ja) |
WO (1) | WO2014186750A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
US10633449B2 (en) | 2013-03-27 | 2020-04-28 | Cedars-Sinai Medical Center | Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway |
US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
US11236393B2 (en) | 2008-11-26 | 2022-02-01 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018523488A (ja) | 2015-08-21 | 2018-08-23 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 自己免疫疾患の治療及び診断のために組み合わせて使用するための組成物及び方法 |
WO2017201461A1 (en) | 2016-05-20 | 2017-11-23 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
EP3846851A4 (en) * | 2018-09-07 | 2022-09-21 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISORDERS OF THE LYMPHATIC SYSTEM |
KR20220088529A (ko) | 2019-05-14 | 2022-06-27 | 프로메테우스 바이오사이언시즈, 인크. | Tl1a 환자 선택 방법, 시스템 및 장치 |
BR112022004590A2 (pt) * | 2019-09-13 | 2022-06-14 | Kyowa Kirin Co Ltd | Variante dcr3 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008106451A2 (en) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
WO2009105590A2 (en) * | 2008-02-19 | 2009-08-27 | The Children's Hospital Of Philadelphia | Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same |
US20110045476A1 (en) * | 2009-04-14 | 2011-02-24 | Prometheus Laboratories Inc. | Inflammatory bowel disease prognostics |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US20100240043A1 (en) * | 2007-10-19 | 2010-09-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
US20120073585A1 (en) * | 2009-04-08 | 2012-03-29 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
MX2013013329A (es) * | 2011-05-20 | 2014-04-16 | Us Government | Bloqueo de interacciones de factor de necrosis tumoral como ligando 1a - receptor de muerte 3 (tl1a-dr3) para mejorar la patologia mediada por las celulas t y los anticuerpos para los mismos. |
-
2014
- 2014-05-16 ES ES18201967T patent/ES2894963T3/es active Active
- 2014-05-16 EP EP18201967.9A patent/EP3498867B1/en active Active
- 2014-05-16 KR KR1020157034355A patent/KR102295125B1/ko active IP Right Grant
- 2014-05-16 JP JP2016514143A patent/JP6482533B2/ja active Active
- 2014-05-16 KR KR1020217026836A patent/KR20210107176A/ko not_active IP Right Cessation
- 2014-05-16 WO PCT/US2014/038468 patent/WO2014186750A2/en active Application Filing
- 2014-05-16 KR KR1020237020524A patent/KR20230093538A/ko not_active Application Discontinuation
- 2014-05-16 EP EP14797214.5A patent/EP2997165A4/en not_active Withdrawn
- 2014-05-16 US US14/890,712 patent/US20160090629A1/en not_active Abandoned
- 2014-05-16 EP EP21193676.0A patent/EP3988673A3/en active Pending
- 2014-05-16 CN CN201480038133.6A patent/CN105358713B/zh active Active
-
2018
- 2018-04-05 US US15/946,632 patent/US20180230543A1/en not_active Abandoned
- 2018-06-29 JP JP2018124311A patent/JP2018148931A/ja not_active Withdrawn
-
2020
- 2020-06-03 JP JP2020096798A patent/JP2020127437A/ja not_active Withdrawn
-
2021
- 2021-08-02 US US17/392,098 patent/US20210371931A1/en active Pending
-
2022
- 2022-06-09 JP JP2022093628A patent/JP2022111329A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
WO2008106451A2 (en) * | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
WO2009105590A2 (en) * | 2008-02-19 | 2009-08-27 | The Children's Hospital Of Philadelphia | Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same |
US20110045476A1 (en) * | 2009-04-14 | 2011-02-24 | Prometheus Laboratories Inc. | Inflammatory bowel disease prognostics |
Non-Patent Citations (5)
Title |
---|
ATSUSHI HIRANO, ET AL.: "Association Study of 71 European Crohn's Disease Susceptibility Loci in a Japanese Population", INFLAMMATORY BOWEL DISEASES, vol. 19, JPN6018011987, 1 March 2013 (2013-03-01), pages 526 - 533, XP055310610, ISSN: 0003903385, DOI: 10.1097/MIB.0b013e31828075e7 * |
B FUNKE, ET AL.: "Functional characterisation of decoy receptor 3 in Crohn's disease", GUT, vol. 58, JPN6018011990, 2009, pages 483 - 491, ISSN: 0003965554 * |
CAMILLE JUNG, ET AL.: "Genotype/Phenotype Analyses for 53 Crohn's Disease Associated Genetic Polymorphisms", PLOS ONE, vol. 7, JPN6018011989, 2012, pages 1 - 10, ISSN: 0003903387 * |
KEIKO YAMAZAKI, ET AL.: "Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease", HUMAN NOLECULAR GENETICS, vol. 14, JPN6018011988, 2005, pages 3499 - 3506, XP009132501, ISSN: 0003903386, DOI: 10.1093/hmg/ddi379 * |
MARK TREMELLING, ET AL: "Contribution of TNFSF15 Gene Variants to Crohn's Disease Susceptibility Confirmed in UK Population", INFLAMMATORY BOWEL DISEASES, vol. 14, JPN6018011986, 2008, pages 733 - 737, XP055310399, ISSN: 0003903384, DOI: 10.1002/ibd.20399 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11236393B2 (en) | 2008-11-26 | 2022-02-01 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-TNFα therapy in inflammatory bowel disease |
US10633449B2 (en) | 2013-03-27 | 2020-04-28 | Cedars-Sinai Medical Center | Treatment and reversal of fibrosis and inflammation by inhibition of the TL1A-DR3 signaling pathway |
US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
US11312768B2 (en) | 2013-07-19 | 2022-04-26 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
US11186872B2 (en) | 2016-03-17 | 2021-11-30 | Cedars-Sinai Medical Center | Methods of diagnosing inflammatory bowel disease through RNASET2 |
Also Published As
Publication number | Publication date |
---|---|
EP3988673A2 (en) | 2022-04-27 |
EP2997165A4 (en) | 2017-03-08 |
EP3498867A1 (en) | 2019-06-19 |
KR102295125B1 (ko) | 2021-08-31 |
KR20210107176A (ko) | 2021-08-31 |
ES2894963T8 (es) | 2022-02-24 |
JP2020127437A (ja) | 2020-08-27 |
EP3988673A3 (en) | 2022-08-03 |
US20210371931A1 (en) | 2021-12-02 |
JP2022111329A (ja) | 2022-07-29 |
WO2014186750A3 (en) | 2015-01-08 |
ES2894963T3 (es) | 2022-02-16 |
JP6482533B2 (ja) | 2019-03-13 |
CN105358713B (zh) | 2020-02-28 |
EP2997165A2 (en) | 2016-03-23 |
US20160090629A1 (en) | 2016-03-31 |
US20180230543A1 (en) | 2018-08-16 |
WO2014186750A2 (en) | 2014-11-20 |
JP2018148931A (ja) | 2018-09-27 |
KR20230093538A (ko) | 2023-06-27 |
EP3498867B1 (en) | 2021-09-29 |
KR20160009582A (ko) | 2016-01-26 |
CN105358713A (zh) | 2016-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6482533B2 (ja) | クローン病に関連するtnfsf15及びdcr3の変異体 | |
Maltby et al. | Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients | |
Vanita et al. | A novel mutation in the DNA‐binding domain of MAF at 16q23. 1 associated with autosomal dominant “cerulean cataract” in an Indian family | |
Wallace et al. | IL-10 genotype analysis in patients with Behçet’s disease | |
RU2593954C2 (ru) | Прогнозирование прогрессирования возрастной макулодистрофии до поздней стадии с помощью полигенного показателя | |
AU2006220604A1 (en) | Diagnostic and therapeutic target for macular degeneration | |
KR101566064B1 (ko) | 연령-관련 황반 변성에서의 유전자 다형성 | |
KR20210049117A (ko) | 기관지 전암성 병변 중증도 및 진행과 관련된 방법 | |
US20160096885A1 (en) | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis | |
Bresam et al. | Polymorphism in SNP rs972283 of the KLF14 gene and genetic disposition to peptic ulcer | |
JP6689743B2 (ja) | 抑うつ症状及び不安症状の少なくとも一方を有する患者におけるバソプレッシン受容体1bアンタゴニストに対する治療応答を予測する方法 | |
Young et al. | Whole genome expression profiling of normal human fetal and adult ocular tissues | |
Evans et al. | Novel 25 kb deletion of MERTK causes retinitis pigmentosa with severe progression | |
Medrano et al. | Response to infliximab in Crohn’s disease: genetic analysis supporting expression profile | |
Grillo et al. | Increased FGF3 and FGF4 gene dosage is a risk factor for craniosynostosis | |
Ewald et al. | A functional variant of the serotonin transporter gene in families with bipolar affective disorder | |
Kashani et al. | Analysis of glutathione S-transferase genes polymorphisms and the risk of schizophrenia in a sample of Iranian population | |
JP7090604B2 (ja) | びまん性大細胞型b細胞リンパ腫の予後予測因子、及び予後予測方法 | |
KR102205831B1 (ko) | 혈중 스타틴 약물농도 예측을 위한 유전자 마커 | |
TW201701897A (zh) | 選擇對醋酸格拉替雷(glatiramer acetate)之反應具預測性之單一核苷酸多型性 | |
JP2008534019A (ja) | ヒトニーマンピックc1様1遺伝子(npc1l1)多型及びその使用方法 | |
WO2023112946A1 (ja) | アルツハイマー病を発症する可能性を判定するためのデータ収集方法及びキット | |
Davatchi et al. | HLA-B51 IN BEHCETS DISEASE | |
McKinney | A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: A case control study in an Italian population |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170425 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181023 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190212 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6482533 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |